Orchid Pharma Limited (ORCHPHARMA)
Monitoring Agency Report
Monitoring Agency Report for Q1 FY27 on QIP proceeds utilization
- No deviation from revised allocation approved by shareholders on Sep 20, 2025
- Revised allocation increased investment in Jammu facility and loan repayment; reduced Alathur API facility spend
- Significant delay in Jammu manufacturing facility; commercial operations expected by Feb 2027
- Total QIP proceeds Rs 394.54 Cr; Rs 357.16 Cr utilized by June 30, 2026
- Unutilized funds Rs 37.38 Cr invested in fixed deposits
- Alathur API block fully utilized; no further investment expected
- Shareholder approvals obtained for material changes
- No government approvals pending as per disclosures
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 ORCHPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add ORCHPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Orchid Pharma Limited
Important.
The summary above is generated automatically from Orchid Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.